AbbVie Inc. Net Income (Loss) Attributable to Noncontrolling Interest
AbbVie Inc. (ABBV) reported Net Income (Loss) Attributable to Noncontrolling Interest of $3.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-08-03
- AbbVie Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-06-30 was $3.00M, a 0.00% change year-over-year.
- AbbVie Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-03-31 was $2.00M, a 33.33% decline year-over-year.
- AbbVie Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$1.00M.
- AbbVie Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was $2.00M, a 33.33% decline year-over-year.
- AbbVie Inc. net income (loss) attributable to noncontrolling interest for fiscal 2025 was $7.00M, a 12.50% decline from fiscal 2024.
- AbbVie Inc. net income (loss) attributable to noncontrolling interest for fiscal 2024 was $8.00M, a 20.00% decline from fiscal 2023.
- AbbVie Inc. net income (loss) attributable to noncontrolling interest for fiscal 2023 was $10.00M, a 11.11% increase from fiscal 2022.
- AbbVie Inc. net income (loss) attributable to noncontrolling interest for fiscal 2022 was $9.00M, a 28.57% increase from fiscal 2021.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.00M 10-Q · filed 2026-08-03 | $5.00M 10-Q · filed 2026-08-03 | $4.00M derived: sum of 3 quarters · filed 2026-08-03 | $6.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $2.00M 10-Q · filed 2026-05-08 | $1.00M derived: sum of 2 quarters · filed 2026-05-08 | $3.00M derived: sum of 3 quarters · filed 2026-05-08 | $6.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.00M derived: sum of 2 quarters · filed 2026-02-20 | $4.00M derived: sum of 3 quarters · filed 2026-08-03 | $7.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | $2.00M 10-Q · filed 2025-11-04 | $5.00M derived: sum of 2 quarters · filed 2026-08-03 | $8.00M 10-Q · filed 2025-11-04 | $7.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $3.00M 10-Q · filed 2026-08-03 | $6.00M 10-Q · filed 2026-08-03 | $5.00M derived: sum of 3 quarters · filed 2026-08-03 | $8.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $3.00M 10-Q · filed 2026-05-08 | $2.00M derived: sum of 2 quarters · filed 2026-05-08 | $5.00M derived: sum of 3 quarters · filed 2026-05-08 | $8.00M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.00M derived: sum of 2 quarters · filed 2026-02-20 | $5.00M derived: sum of 3 quarters · filed 2026-02-20 | $8.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | $3.00M 10-Q · filed 2025-11-04 | $6.00M derived: sum of 2 quarters · filed 2025-11-04 | $9.00M 10-Q · filed 2025-11-04 | $11.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $3.00M 10-Q · filed 2025-08-04 | $6.00M 10-Q · filed 2025-08-04 | $8.00M derived: sum of 3 quarters · filed 2026-02-20 | $11.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $3.00M 10-Q · filed 2025-05-09 | $5.00M derived: sum of 2 quarters · filed 2026-02-20 | $8.00M derived: sum of 3 quarters · filed 2026-02-20 | $11.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $5.00M derived: sum of 2 quarters · filed 2026-02-20 | $8.00M derived: sum of 3 quarters · filed 2026-02-20 | $10.00M 10-K · filed 2026-02-20 |
| 2023-09-30 | $3.00M 10-Q · filed 2024-11-04 | $6.00M derived: sum of 2 quarters · filed 2024-11-04 | $8.00M 10-Q · filed 2024-11-04 | $7.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $3.00M 10-Q · filed 2024-08-07 | $5.00M 10-Q · filed 2024-08-07 | $4.00M derived: sum of 3 quarters · filed 2025-02-14 | $7.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $2.00M 10-Q · filed 2024-05-03 | $1.00M derived: sum of 2 quarters · filed 2025-02-14 | $4.00M derived: sum of 3 quarters · filed 2025-02-14 | $8.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $2.00M derived: sum of 2 quarters · filed 2025-02-14 | $6.00M derived: sum of 3 quarters · filed 2025-02-14 | $9.00M 10-K · filed 2025-02-14 |
| 2022-09-30 | $3.00M 10-Q · filed 2023-11-06 | $7.00M derived: sum of 2 quarters · filed 2023-11-06 | $10.00M 10-Q · filed 2023-11-06 | $11.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $4.00M 10-Q · filed 2023-08-07 | $7.00M 10-Q · filed 2023-08-07 | $8.00M derived: sum of 3 quarters · filed 2024-02-20 | $9.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $3.00M 10-Q · filed 2023-05-05 | $4.00M derived: sum of 2 quarters · filed 2024-02-20 | $5.00M derived: sum of 3 quarters · filed 2024-02-20 | $8.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $2.00M derived: sum of 2 quarters · filed 2024-02-20 | $5.00M derived: sum of 3 quarters · filed 2024-02-20 | $7.00M 10-K · filed 2024-02-20 |
| 2021-09-30 | $1.00M 10-Q · filed 2022-11-04 | $4.00M derived: sum of 2 quarters · filed 2022-11-04 | $6.00M 10-Q · filed 2022-11-04 | $8.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $3.00M 10-Q · filed 2022-08-04 | $5.00M 10-Q · filed 2022-08-04 | $7.00M derived: sum of 3 quarters · filed 2023-02-17 | $12.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $2.00M 10-Q · filed 2022-05-06 | $4.00M derived: sum of 2 quarters · filed 2023-02-17 | $9.00M derived: sum of 3 quarters · filed 2023-02-17 | $8.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $7.00M derived: sum of 2 quarters · filed 2023-02-17 | $6.00M derived: sum of 3 quarters · filed 2023-02-17 | $6.00M 10-K · filed 2023-02-17 |
| 2020-09-30 | $5.00M 10-Q · filed 2021-11-02 | $4.00M derived: sum of 2 quarters · filed 2021-11-02 | $4.00M 10-Q · filed 2021-11-02 | $4.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | -$1.00M 10-Q · filed 2021-08-02 | -$1.00M 10-Q · filed 2021-08-02 | -$1.00M derived: sum of 3 quarters · filed 2022-02-18 | -$1.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | $0.00 derived: sum of 2 quarters · filed 2022-02-18 | $0.00 derived: sum of 3 quarters · filed 2022-02-18 | $0.00 derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $0.00 derived: sum of 2 quarters · filed 2022-02-18 | $0.00 derived: sum of 3 quarters · filed 2022-02-18 | $0.00 10-K · filed 2022-02-18 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-04 | $0.00 derived: sum of 2 quarters · filed 2020-11-04 | $0.00 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-04 | $0.00 10-Q · filed 2020-08-04 | ||
| 2018-12-31 | $0.00 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |